Good Things Come in 3’s!
Niccolo, Alessandro and Sammy are among nearly 100 children and young adults with Progeria across the world who are benefitting from the life-extending, FDA-approved lonafarnib drug. PRF will continue to devote funds to ensure access to lonafarnib for all, and to study its long-term effects.
But we won’t stop there.
PRF is exploring 3 other therapeutic pathways
to treat and cure Progeria, attacking this disease:
at the Protein, at the RNA, and at the DNA levels!
SMALL MOLECULE DRUGS
WHAT is PRF’s role? PRF is collaborating with the biotech company PRGS&T to begin a new clinical trial exploring whether Ionafarnib, in combination with a new drug called progerinin, is more effective than Ionafarnib alone.
WHY is it promising? This new drug increased lifespan in a Progeria mouse model by 50%.
RNA THERAPEUTICS
WHAT is PRF’s role? PRF is the drug developer (or “sponsor”). This means PRF assumes responsibility and costs for drug manufacturing, pre-trial animal and cellular studies, and clinical trials conducted by world-class scientific experts.
WHY is it promising? The RNA therapeutic resulted in a 62% increase in Progeria mouse lifespan.
DNA BASE EDITING
WHAT is PRF’s role? PRF will fund drug manufacturing, pre-trial animal and cellular studies, and clinical trials conducted by world-class scientific experts.
WHY is it promising? In the Progeria mouse model, lifespan was extended by 140%, approaching what is normally old age for healthy mice. This is a one-time injection that could be our pathway to the CURE!
Science is a costly endeavor, and with your ongoing support, we will continue to
push the boundaries of science toward the cure.